GeneDx Hldgs (NASDAQ:WGSWW) Stock, Quote.Headers.trade-ideas

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

GeneDx Holdings Corp

The Q3 earnings report for HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) was released on Monday, December 9, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights into HealthEquity Q3 Earnings

MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
MongoDB beat estimated earnings by 68.0%, reporting an EPS of $1.16 versus an estimate of $0.69.
Revenue was up $96.44 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.21 in the previous quarter, leading to a 18.0% increase share price change the next day.
Here's a look at MongoDB's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.40</td>
<td>0.47</td>
<td>0.50</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.51</td>
<td>0.86</td>
<td>0.96</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>464.14M</td>
<td>439.64M</td>
<td>433.73M</td>
<td>403.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>478.11M</td>
<td>450.56M</td>
<td>458.00M</td>
<td>432.94M</td>
</tr>
</tbody>
</table>

To track all earnings releases for MongoDB <a href="https://www.benzinga.com/quote/MDB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: MongoDB Q3

Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/12/g42400873/toll-brothers-reports-fy-2024-results">details from the report.</a>
The Details: Toll Brothers reported quarterly earnings of $4.63 per share, which beat the analyst consensus estimate of $4.33. Quarterly revenue came in at $3.33 billion, which beat the analyst consensus estimate of $3.17 billion and is an increase over sales of $3.02 billion from the same period last year.
<ul>
<li>Home sales revenues were $3.26 billion, up 10% compared to 2023&#8217;s fourth quarter. </li>
<li>Delivered homes were 3,431, up 25%.</li>
<li>Net signed contract value was $2.66 billion, up 32% compared to 2023&#8217;s fourth quarter.</li>
<li>Contracted homes were 2,658, up 30%.</li>
<li>Backlog value was $6.47 billion at the fourth quarter end, down 7% compared to 2023&#8217;s fourth quarter.</li>
<li>Homes in backlog were 5,996, down 9%.</li>
<li>Home sales gross margin was 26%, compared to 2023&#8217;s fourth quarter home sales gross margin of 27.5%.</li>
<li>Adjusted home sales gross margin, which excludes interest and inventory write-downs, was 27.9%, compared to 2023&#8217;s fourth quarter adjusted home sales gross margin of 29.1%.</li>
</ul>
Read More: <a href="https://www.benzinga.com/general/social-media/24/12/42378469/anthony-scaramucci-compares-trumps-fbi-pick-kash-patel-to-matt-gaetz">Anthony Scaramucci Compares Trump&#8217;s FBI Pick, Kash Patel, To Matt Gaetz</a>
Toll Brothers will. host a conference call to discuss the results at 8:30 a.m. ET Tuesday.
&#8220;I am very pleased with our fourth quarter results, which cap the strongest year ever for Toll Brothers. For the full year, we generated a record $10.6 billion of home sales revenue, earned $15.01 per diluted share and grew contracts by 27% in both units and dollars,&#8221; said Douglas C. Yearley Jr., CEO of Toll Brothers.
Outlook:&nbsp;Toll Brothers expects deliveries of between 1,900 and 2,100 units in the first quarter and deliveries of between 11,200 and 11,600 units for fiscal 2025. 
TOL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Toll Brothers shares are down 2.42% after-hours at $152.70 at the time of publication Monday.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42374462/robinhood-markets-grows-into-best-in-class-brokerage-analyst-says">Robinhood Markets Grows Into &#8216;Best-In-Class&#8217; Brokerage, Analyst Says</a></li>
</ul>
Image: Shutterstock

News

After-Hours Center

Movers

Real Estate

Toll Brothers Reports Better-Than-Expected Q4 Results, Weak Q1 Home Deliveries Guidance: Details

TJX Companies CEO & President Herrman Ernie Sells 7,533 Shares At $126.1849 Each

Rupert Murdoch's attempt to change the billion-dollar family trust to favor his eldest son, Lachlan, <a href="https://www.benzinga.com/topic/fox-news">hit a roadblock</a>. 
What Happened: In a ruling that reads like an episode of &#8220;Succession,&#8221; Commissioner Edmund J. Gorman Jr. essentially threw cold water on Murdoch's trust fund shuffle.
According to the <a href="https://www.nytimes.com/2024/12/09/business/media/rupert-lachlan-murdoch-family-trust.html?campaign_id=190&amp;emc=edit_ufn_20241209&amp;instance_id=141779&amp;nl=from-the-times&amp;regi_id=136109156&amp;segment_id=185282&amp;user_id=e415429009fa21c5b8b4141c24d72bca">New York Times</a>, Gorman&#8217;s scathing critique of Murdoch came across in a 96-page document. The plan to "permanently cement Lachlan Murdoch's executive roles" inside the family&#8217;s media empire seemed like a "carefully crafted charade," Gorman wrote.
See Also: <a href="https://www.benzinga.com/news/23/09/34746546/new-book-reveals-how-rupert-murdochs-miscalculations-on-dominion-lawsuit-cost-him-over-700m" target="_blank" rel="noreferrer noopener">New Book Reveals How Rupert Murdoch&#8217;s Miscalculations On Dominion Lawsuit Cost Him Over $700M</a>
Murdoch reportedly planned to amend the family trust, potentially solidifying Lachlan&#8217;s role in overseeing Fox News and its editorial direction.
The problem? Fairness. The trust, as it stands, gives equal control to Murdoch's four oldest children: Lachlan, James, Elisabeth, and Prudence. 
While Lachlan currently holds the roles of executive chairman and CEO of Fox Corporation and chairman of News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>), he does not have full control of the company.
Murdoch's other children — James, Elisabeth and Prudence — reportedly oppose the trust amendment. They&#8217;re also believed to be less conservative than Lachlan, per <a href="https://www.theguardian.com/media/2024/dec/09/rupert-murdochmedia-empire-children">The Guardian</a>.
Why It Matters: Murdoch, 93, a billionaire media mogul known for his role in shaping modern cable programming, faces a high-profile legal ruling that some see as a significant setback.
The Murdoch media empire extends beyond Fox News to include The Wall Street Journal and The New York Post, which are often characterized by their conservative editorial stances.
While <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41034849/fox-stock-thrives-on-sports-politics-strategy-analyst-says-it-will-weather-secular-">good for ratings</a> and readership, that take has cost Murdoch millions in legal penalties.
Recall last year when Fox had to pay a <a href="https://www.benzinga.com/news/23/04/31870703/fox-dominion-reach-787-5m-settlement-in-defamation-case-over-2020-presidential-election-falsehoods" target="_blank" rel="noreferrer noopener">record $787.5 million settlement </a>in a defamation lawsuit from Dominion Voting Systems. Murdoch and company defended against allegations that they made false claims about the 2020 election.
What&#8217;s Next: The family squabble is unlikely to end soon, as Murdoch's lawyer, Adam Streisand, has promised to appeal.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42327943/trump-could-nominate-former-political-foe-desantis-for-defense-secretary-over-hegseth-report-says-here-are-the-polymarket-odds-for-presidents-cabinet-pick">Trump To Swap Former Fox News Host For DeSantis? Here&#8217;s What Polymarket Odds For Defense Secretary Pick Show</a></li>
</ul>
Image: Shutterstock

Entertainment

Legal

Media

NWSA

Murdoch Succession Plan Faces Setback As Commissioner Rejects Eldest Son's Control

MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) released its Q3 earnings on Monday, December 9, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
MongoDB beat estimated earnings by 68.0%, reporting an EPS of $1.16 versus an estimate of $0.69.
Revenue was up $96.44 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.21, resulting in a 18.0% increase change in the share price the following day.
Here's a look at MongoDB's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.49</td>
<td>0.40</td>
<td>0.47</td>
<td>0.50</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.70</td>
<td>0.51</td>
<td>0.86</td>
<td>0.96</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>464.14M</td>
<td>439.64M</td>
<td>433.73M</td>
<td>403.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>478.11M</td>
<td>450.56M</td>
<td>458.00M</td>
<td>432.94M</td>
</tr>
</tbody>
</table>

To track all earnings releases for MongoDB <a href="https://www.benzinga.com/quote/MDB/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MongoDB: Q3 Earnings Insights

NYSE To Begin Delisting Proceedings Against The Container Store Group

As discussed during the Company's 2024 Analyst &amp; Investor Day,&nbsp;it expects 2025 Free Cash Flow of $16 billion+, when excluding DIRECTV.&nbsp;
The expected drivers of next year's free cash flow growth include Adjusted EBITDA growth, lower cash interest from lower debt balances, the absence of network termination fee payments in 2025 and lower working capital impacts in 2025 compared to 2024. These items are expected to more than offset an expected increase in cash taxes.
The Company continues to expect to achieve its net leverage target of net-debt-to-adjusted EBITDA in the 2.5x range in the first half of 2025 and maintain leverage within this range through 2027.
The Company expects to return $40 billion+ of this financial capacity to shareholders through dividends and share repurchases. Under this capital return plan, the Company expects to maintain its current annualized common stock dividend of $1.11 per share. This plan would result in $20 billion+ in total dividend payments, with capacity for about $20 billion in share repurchases, from 2025-2027.
 &nbsp;

Guidance

AT&T Expects Its Multi-year Strategic Plan To Provide $50B+ Of Financial Capacity Over Next Three Years, Largely Through Organic Growth

In Mobility, the Company is building a more efficient, high-capacity, programmable and open network. By 2027, it expects to have largely completed the modernization of its 5G wireless network with open technology, with deep mid-band 5G spectrum covering 300 million+ people by the end of 2026.
&nbsp;
 &nbsp;

AT&T Says Remains On Track To Meet All Of The Financial And Operational Guidance Shared During Its 2024 Analyst & Investor Day

MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) reported its third-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/12/n42399751/mongodb-inc-announces-third-quarter-fiscal-2025-financial-results">key figures from the quarter. </a>
The Details: MongoDB reported quarterly earnings of $1.16 per share, which beat the analyst consensus estimate of 69 cents. Quarterly revenue came in at $529.4 million, which beat the consensus estimate of $497.75 and is an increase over sales of $432.938 million from the same period last year.
Subscription revenue was $512.2 million, an increase of 22% year-over-year, and services revenue was $17.2 million, an increase of 18% year-over-year. Non-GAAP gross profit was $405.7 million, representing a 77% non-GAAP gross margin, consistent with a non-GAAP gross margin of 77% in the year-ago period.
Read More: <a href="https://www.benzinga.com/general/social-media/24/12/42378469/anthony-scaramucci-compares-trumps-fbi-pick-kash-patel-to-matt-gaetz">Anthony Scaramucci Compares Trump&#8217;s FBI Pick, Kash Patel, To Matt Gaetz</a>
&#8220;MongoDB&#8217;s third-quarter results were significantly ahead of expectations on the top and bottom line, driven by better-than-expected EA performance and 26% Atlas revenue growth. We continue to see success winning new business due to the superiority of MongoDB&#8217;s developer data platform in addressing a wide variety of mission-critical use cases,&#8221; said Dev Ittycheria, president and CEO of MongoDB.
MongoDB also announced its COO and CFO Michael Gordon will step down on Jan. 31, 2025. Serge Tanjga has been named Interim CFO starting Feb. 1, if no other candidate is appointed.
Outlook: MongoDB sees fourth-quarter revenue of between $515 million and $519 million, versus the $506.13 million estimate, and adjusted earnings of between 62 cents and 65 cents per share, versus the 56 cent estimate.
The company expects fiscal 2025 revenue in a range of $1.973 billion to $1.977 billion, versus the $1.93 billion estimate, and adjusted earnings of between $3.01 and $3.03 per share, versus the $2.47 estimate. 
MDB Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MongoDB shares are up 8.90% after-hours at $381.30 at the time of publication Monday. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42374462/robinhood-markets-grows-into-best-in-class-brokerage-analyst-says">Robinhood Markets Grows Into &#8216;Best-In-Class&#8217; Brokerage, Analyst Says</a></li>
</ul>
Image: Shutterstock

Tech

MongoDB Shares Climb After Blockbuster Q3 Results, FY25 Guidance Above Estimates

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 5.0% increase share price change the next day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Breakdown: HealthEquity Q3

The Q4 earnings report for Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) was released on Monday, December 9, 2024 at 04:30 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Toll Brothers beat estimated earnings by 7.000000000000001%, reporting an EPS of $4.63 versus an estimate of $4.34.
Revenue was up $313.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.29 in the previous quarter, leading to a 6.0% increase share price change the next day.
Here's a look at Toll Brothers's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.31</td>
<td>4.14</td>
<td>1.78</td>
<td>3.72</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.60</td>
<td>3.38</td>
<td>2.25</td>
<td>4.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>2.71B</td>
<td>2.53B</td>
<td>1.86B</td>
<td>2.77B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.73B</td>
<td>2.84B</td>
<td>1.95B</td>
<td>3.02B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Toll Brothers <a href="https://www.benzinga.com/quote/TOL/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Toll Brothers Q4 Earnings

OCEA

Ocean Biomedical Receives Nasdaq Non-Compliance Notice For Minimum Bid Price

Since Colorado and Washington took the historic step of legalizing recreational cannabis in 2014, the marijuana industry has rapidly expanded, with tax revenue emerging as one of the most significant financial outcomes.
The growing legal cannabis market across the U.S. has generated billions of dollars in tax revenue, benefitting state budgets, funding essential services and providing economic boosts in both mature and newly legal markets. According to the<a href="https://www.fool.com/research/marijuana-tax-revenue-by-state/"> latest figures</a> compiled by <a href="https://www.fool.com/author/20014/">Lyle Daly</a> for The Motley Fool, based on official websites and the <a href="https://www.benzinga.com/general/biotech/24/06/39173830/cannabis-taxes-weight-potency-or-price-impact-on-businesses-patients-consumers">Tax Foundation</a>, states that have not yet legalized are missing out on nearly $5 billion in tax revenue.
<h3 class="wp-block-heading">Cannabis Tax Leaders</h3>
In 2023, California raked in over $1.08 billion in cannabis <a href="https://www.benzinga.com/markets/cannabis/23/12/36040887/california-cannabis-taxes-hit-270m-in-q3-funding-used-for-research-social-initiatives-schools-mo">tax revenue</a> &#8211; a number that underscores the scale of the state&#8217;s weed market. Other states, like <a href="https://www.benzinga.com/topic/Illinois-cannabis">Illinois</a> and <a href="https://www.benzinga.com/topic/washington-cannabis">Washington</a> also collected hundreds of millions in tax revenue. The table below outlines cannabis tax revenue collected by each state in their most recent fiscal or calendar year and considering all cannabis markets.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Order</td>
<td>State</td>
<td>Revenue</td>
</tr>
<tr>
<td>1</td>
<td>California</td>
<td>1.089.898.823,00</td>
</tr>
<tr>
<td>2</td>
<td>Washington</td>
<td>464.496.959,00</td>
</tr>
<tr>
<td>3</td>
<td>Illinois</td>
<td>451.868.765,00</td>
</tr>
<tr>
<td>4</td>
<td>Michigan</td>
<td>290.300.000,00</td>
</tr>
<tr>
<td>5</td>
<td>Arizona</td>
<td>289.879.253,00</td>
</tr>
<tr>
<td>6</td>
<td>Colorado</td>
<td>274.121.043,00</td>
</tr>
<tr>
<td>7</td>
<td>Massachusetts</td>
<td>272.445.292,00</td>
</tr>
<tr>
<td>8</td>
<td>Oregon</td>
<td>150.898.047,00</td>
</tr>
<tr>
<td>9</td>
<td>Nevada</td>
<td>120.537.308,00</td>
</tr>
<tr>
<td>10</td>
<td>Missouri</td>
<td>74.254.000,00</td>
</tr>
<tr>
<td>11</td>
<td>Montana</td>
<td>54.075.570,00</td>
</tr>
<tr>
<td>12</td>
<td>New York</td>
<td>50.760.000,00</td>
</tr>
<tr>
<td>13</td>
<td>New Mexico</td>
<td>47.243.651,00</td>
</tr>
<tr>
<td>14</td>
<td>New Jersey</td>
<td>41.889.891,00</td>
</tr>
<tr>
<td>15</td>
<td>Maine</td>
<td>35.593.347,00</td>
</tr>
<tr>
<td>16</td>
<td>Maryland</td>
<td>29.880.000,00</td>
</tr>
<tr>
<td>17</td>
<td>Alaska</td>
<td>29.477.517,00</td>
</tr>
<tr>
<td>18</td>
<td>Connecticut</td>
<td>24.613.366,00</td>
</tr>
<tr>
<td>19</td>
<td>Rhode Island</td>
<td>17.203.256,00</td>
</tr>
<tr>
<td>20</td>
<td>Vermont</td>
<td>15.210.000,00</td>
</tr>
</tbody>
</table>
</figure>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41257214/2024-cannabis-taxes-states-weigh-in-on-new-approaches-to-revenue">2024 Cannabis Taxes: States Weigh In On New Approaches To Revenue</a>
<h3 class="wp-block-heading">States Still Leaving Revenue On the Table</h3>
Despite the rapid spread of cannabis legalization, many states have yet to tap into the potential revenue, leaving millions to <a href="https://www.benzinga.com/markets/cannabis/24/09/41002430/illicit-cannabis-market-balloons-to-79-billion-is-rescheduling-enough-to-fix-the-system">illicit markets</a>.
According to estimates from the Tax Foundation, states that have not yet legalized cannabis could be losing out on billions of dollars in tax revenue.
The table below highlights the projected cannabis tax revenue for these states if they were to legalize cannabis in the near future. 
As you can see, Florida has left a massive amount of tax revenue after <a href="https://www.benzinga.com/markets/cannabis/24/11/41763514/florida-rejects-cannabis-legalization-amendment-supported-by-trump-detested-by-desantis">Amendment 3 failed garner </a> the necessary 60% of the vote to enact an amendment.
Overall, the leader is <a href="https://www.benzinga.com/topic/texas-cannabis">Texas</a>, the second largest economy in the U.S. after California.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Order</td>
<td>State</td>
<td>Revenue</td>
</tr>
<tr>
<td>1</td>
<td>Texas</td>
<td>492.056.337,00</td>
</tr>
<tr>
<td>2</td>
<td>Florida</td>
<td>454.981.259,00</td>
</tr>
<tr>
<td>3</td>
<td>Pennsylvania</td>
<td>315.223.591,00</td>
</tr>
<tr>
<td>4</td>
<td>Georgia</td>
<td>250.470.344,00</td>
</tr>
<tr>
<td>5</td>
<td>Virginia</td>
<td>211.857.590,00</td>
</tr>
<tr>
<td>6</td>
<td>North Carolina</td>
<td>197.164.241,00</td>
</tr>
<tr>
<td>7</td>
<td>Indiana</td>
<td>172.219.718,00</td>
</tr>
<tr>
<td>8</td>
<td>Tennessee</td>
<td>155.646.987,00</td>
</tr>
<tr>
<td>9</td>
<td>Minnesota</td>
<td>143.003.873,00</td>
</tr>
<tr>
<td>10</td>
<td>Wisconsin</td>
<td>133.094.405,00</td>
</tr>
<tr>
<td>11</td>
<td>Oklahoma</td>
<td>128.481.377,00</td>
</tr>
<tr>
<td>12</td>
<td>Louisiana</td>
<td>116.350.821,00</td>
</tr>
<tr>
<td>13</td>
<td>South Carolina</td>
<td>110.883.529,00</td>
</tr>
<tr>
<td>14</td>
<td>Kentucky</td>
<td>92.260.563,00</td>
</tr>
<tr>
<td>15</td>
<td>Alabama</td>
<td>86.622.418,00</td>
</tr>
<tr>
<td>16</td>
<td>Iowa</td>
<td>83.888.771,00</td>
</tr>
<tr>
<td>17</td>
<td>Kansas</td>
<td>74.833.568,00</td>
</tr>
<tr>
<td>18</td>
<td>Arkansas</td>
<td>63.215.571,00</td>
</tr>
<tr>
<td>19</td>
<td>Mississippi</td>
<td>60.481.925,00</td>
</tr>
<tr>
<td>20</td>
<td>Utah</td>
<td>58.260.837,00</td>
</tr>
<tr>
<td>21</td>
<td>West Virginia</td>
<td>41.175.548,00</td>
</tr>
<tr>
<td>22</td>
<td>Idaho</td>
<td>38.783.607,00</td>
</tr>
<tr>
<td>23</td>
<td>Nebraska</td>
<td>37.245.931,00</td>
</tr>
<tr>
<td>24</td>
<td>New Hampshire</td>
<td>36.733.372,00</td>
</tr>
<tr>
<td>25</td>
<td>Hawaii</td>
<td>28.361.581,00</td>
</tr>
<tr>
<td>26</td>
<td>Delaware</td>
<td>26.482.199,00</td>
</tr>
<tr>
<td>27</td>
<td>North Dakota</td>
<td>16.743.584,00</td>
</tr>
<tr>
<td>28</td>
<td>South Dakota</td>
<td>16.060.172,00</td>
</tr>
<tr>
<td>29</td>
<td>Wyoming</td>
<td>13.668.232,00</td>
</tr>
</tbody>
</table>
</figure>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Long-Term Potential</h3>
Looking ahead, states that have legalized marijuana will continue to see tax revenue grow as markets mature and demand stabilizes. 
Early adopters have already seen billions in revenue, while newer markets like Michigan and Illinois are catching up quickly.
As more states <a href="https://www.benzinga.com/topic/cannabis-legalization">legalize cannabis</a>, especially in the wake of budget deficits and increased pressure on public services, marijuana tax revenue could play a critical role in financing key state priorities, from education to infrastructure.
States still hesitant about legalization should consider the economic benefits already realized by their peers. As the data shows, legal cannabis is not just a societal shift but a financial one, with states that embrace it reaping significant rewards.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/24/11/42224446/the-hidden-cost-of-legal-weed-why-marijuana-taxes-are-hitting-your-wallet-harder-than-you-think">The Hidden Cost Of Legal Weed: Why Marijuana Taxes Are Hitting Your Wallet Harder Than You Think</a></li>
</ul>
COVER: AI Generated Image

Cannabis

Markets

States Without Legal Cannabis Are Missing Out On Billions In Annual Tax Revenue, New Analysis Shows

Common Dividends for 2024 Total $0.32 Per Share
BETHESDA, Md., Dec. 9, 2024 /PRNewswire/ -- DiamondRock Hospitality Company (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) announced that its Board of Directors has declared a fourth quarter dividend of $0.23 per common share, which includes the Company's regular quarterly dividend of $0.03 per common share, along with a stub dividend of $0.20 per common share. The dividend will be paid on January 14, 2025 to shareholders of record as of December 31, 2024.

Dividends

DiamondRock Hospitality Declared A Q4 Dividend Of $0.23 Per Common Share, Which Includes The Company's Regular Quarterly Dividend Of $0.03 Per Common Share, Along With A Stub Dividend Of $0.20 Per Common Share.

Buybacks

Butterfield Announces $100M Share Repurchase Program Authorizing Buyback Of Up To 2.7M Shares Through December 31, 2025

Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) ("Crane" or the "Company"), a premier industrial manufacturing and technology company, has promoted Alejandro (Alex) Alcala to Chief Operating Officer (COO), effective immediately. In this role, Alex will provide both strategic and operational oversight of all Crane business segments, as well as the Crane Business System organization.

Management

Crane Company Announces Promotion Of Alejandro Alcala To Chief Operating Officer, Effective Immediately

HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) announced its Q3 earnings on Monday, December 9, 2024 at 04:01 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
HealthEquity beat estimated earnings by 8.0%, reporting an EPS of $0.78 versus an estimate of $0.72.
Revenue was up $51.21 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.16 in the last quarter, resulting in a 5.0% increase share price change the following day.
Here's a look at HealthEquity's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.70</td>
<td>0.66</td>
<td>0.56</td>
<td>0.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.80</td>
<td>0.63</td>
<td>0.6</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>284.87M</td>
<td>278.11M</td>
<td>258.55M</td>
<td>243.61M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>299.93M</td>
<td>287.60M</td>
<td>262.39M</td>
<td>249.22M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
HealthEquity management provided guidance for FY 2025, expecting earnings between $3.08 and $3.16 per share.
To track all earnings releases for HealthEquity <a href="https://www.benzinga.com/quote/HQY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HealthEquity Earnings Analysis: Q3 Recap

WKHS

Workhorse Group Announces Grant Thornton Declines Reappointment As Independent Auditor For 2024; No Disagreements Reported On Financial Practices, But Material Weaknesses In Internal Controls Cited, Including Issues With Convertible Note Valuation And Accounting Staff Turnover

– Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma –
– ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients –
– Real-World Evidence Analysis Shows High Effectiveness and Safety Profile Consistent with ZUMA-3 in Broader Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Population –
Kite, a Gilead Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus&#xAE; (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
The data presented include an oral presentation (Abstract # 748) of a primary analysis of ZUMA-2 cohort 3 demonstrating an overall response rate (ORR) of 91% and complete response (CR) rate of 73% in Bruton tyrosine kinase inhibitor (BTKi)-naïve patients with R/R MCL. Long-term follow-up of patients in ZUMA-2 cohorts 1 and 2 (Abstract #4388), showed that 39% of patients with R/R MCL were still alive after five years, underscoring Tecartus as the only CAR T to have five-year follow-up data in this patient population. In addition, real-world evidence outcomes in adults with R/R B-ALL treated with Tecartus (Abstract # 5092 and #4193) demonstrated a high effectiveness and consistent safety profile in a broader patient population than the pivotal ZUMA-3 study.

Biotech

General

GILD

Kite, A Gilead Company Presents Longest Follow-Up Data Reported For Tecartus CAR T-Cell Therapy At ASH 2024 Reinforce Durable Efficacy And Survival Benefits; ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, In Bruton Tyrosine Kinase Inhibitor-Naïve R/R MCL Patients

GeneDx Holdings Corp. 2023 Q4 - Results - Earnings Call Presentation

GeneDx Holdings Corp. (WGS) Q4 2023 Earnings Call Transcript

GeneDx Holdings Corp. (WGS) Q1 2024 Earnings Call Transcript

Small-Cap Stocks 2024 Second Half Outlook - Buy Small Caps

Healthcare 2024 Second Half Outlook

GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript

GeneDx Holdings Corp. 2024 Q2 - Results - Earnings Call Presentation

Not Enough To Keep OPKO Health Flying

GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript

Stock Pickers Better Know When They're Going To Sell

AAPL

ACLS

ALNY

AMGN

AMSC

AMZN

AOSL

ASPN

AZNCF

CDNA

CECO

CLBT

CLBTW

DRUG

ENVX

ETSY

GEHC

GKOS

GOOG

GOOGL

HALO

HIMS

ISRG

MSFT

NFLX

NONOF

NTRA

NVSEF

OKLO

PLSE

PLTR

PODD

PRCT

PSIX

RBLX

RDNT

ROOT

RXST

SMCI

SPYI

TACPF

TMDX

TNDM

TNSSF

TSLA

TSLTF

TWST

VERX

VRTX

WGSWW

ZETA

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

GeneDx Hldgs

GeneDx Hldgs (WGSWW) Forecast

GeneDx Hldgs (NASDAQ:WGSWW) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga